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Abstract Analysis of G-protein-coupled receptor (GPCR)
signaling, in particular of the second messenger cAMP that is
tightly controlled by Gs- and Gi/o-proteins, is a central issue in
biomedical research. The classical biochemical method to
monitor increases in intracellular cAMP concentrations con-
sists of a radioactive multicellular assay, which is well
established, highly sensitive, and reproducible, but precludes
continuous spatial and temporal assessment of cAMP levels in
single living cells. For this purpose, Förster resonance energy
transfer (FRET)-based Epac cAMP sensors are well suitable.
So far, the latter sensors have been employed to monitor
Gs-induced cAMP increases and it has remained elusive
whether Epac sensors can reliably detect decreased intracellu-
lar cAMP levels as well. In this study, we systematically opti-
mize experimental strategies employing FRET-based cAMP
sensors to monitor Gi/o-mediated cAMP reductions. FRET ex-
periments with adrenergic α2A or μ opioid receptors and a set
of different Epac sensors allowed for time-resolved, valid, and
reliable detection of cAMP level decreases upon Gi/o-coupled
receptor activation in single living cells, and this effect can be
reversed by selective receptor antagonists. Moreover,
pre-treatment with forskolin or 3-isobutyl-1-methylxanthine
(IBMX) to artificially increase basal cAMP levels was not
required to monitor Gi/o-coupled receptor activation. Thus,
using FRET-based cAMP sensors is of major advantage when
compared to classical biochemical and multi-cellular assays.
Keywords cAMP . FRET . Epac sensor . Gi/o-coupled
receptors . Gs-coupled receptors
Introduction
G-protein-coupled receptors (GPCRs) constitute a large fam-
ily of membrane proteins that transduce extracellular signals
into cellular responses by activating intracellular signal trans-
duction pathways. GPCRs are commonly activated by a pleth-
ora of small molecules and hormones, and some GPCRs can
even perceive physical and chemical cues such as mechanical
forces (summarized in [28]), voltage [2, 3, 22, 23], or ions
[29]. Since GPCRs are involved in many physiological and
pathophysiological processes and represent molecular targets
for about 30% of all approved drugs [20], a detailed analysis
of GPCRs and their signaling pathways is of utmost impor-
tance and may be leveraged to further improve medical treat-
ment. The two best characterized families of effector enzymes
regulated by GPCRs are phospholipases C (PLC) and
adenylyl cyclases (ACs). Several members of the former en-
zyme family are activated by Gq/11-proteins. Intracellular
cAMP levels can either be elevated as a consequence of Gs-
protein-dependent activation of ACs or decreased following
engagement of Gi/o-protein-coupled receptors resulting in in-
hibition of AC [12]. Thus, the second messenger cAMP is
tightly regulated by Gs- and Gi/o-coupled receptors.
To monitor variations of intracellular cAMP concentrations
in living cells, biochemical approaches are frequently chosen.
The classical method to detect receptor-mediated cAMP
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accumulation in intact cells is based on pre-labelingwith 3H-
adenine and subsequent calculation of the conversion to 3H-
cAMP extracted from cell homogenates [24]. This radioac-
tive, multi-cell-based method is highly sensitive and repro-
ducible especially formonitoringGs-protein-induced cAMP
increases. However, to analyze Gi/o-protein-induced cAMP
level decreases, physiologically low basal cAMP concentra-
tions must be artificially increased by using the AC activator
forskolin and/or the phosphodiesterase inhibitor IBMX.
These measures might impact the validity and reliability of
the assay and decrease the potency of Gi/o-coupled receptor
agonists. Another major drawback of the latter method is the
lack of time-resolved and spatial assessment of cAMP fluc-
tuations in single living cells. These limitations can be over-
come by exploiting Förster resonance energy transfer
(FRET) within exchange proteins directly activated by
cAMP (Epac) that undergo a conformational change after
cAMP binding [25]. This optical method is based on Epac1
or Epac2 proteins N- and C-terminally fused to two
fluorophores, e.g., yellow fluorescent protein (YFP) and cy-
an fluorescent protein (CFP) with YFP representing the ac-
ceptor andCFP the donor of the fluorescence signal. Binding
of cAMP to Epac results in a conformational change altering
the distance between the two fluorophores and decreasing
FRET signals [6, 17, 21] (for a schematic illustration, see
Fig. 1a, inset). Until now, several Epac-based FRETsensors
have been devised. These sensors are either based on Epac1
or Epac2 or on optimized Epac proteins. One of these opti-
mized Epac proteins lacks the membrane-targeting DEP se-
quence (ΔDEP), and the catalytically active guanine nucle-
otide exchange factor (GEF) domain is disabled by a point
mutation [21]. This cytoplasmic sensor detects cAMP
changes in the physiological range from 0.1 to 100 μM [21]
with improved FRET responses compared to Epac1- and
Epac2-based sensors displaying EC50 values of 2.4 μM for
YFP-Epac1-CFP and 0.9 μM for YFP-Epac2-CFP [17].
These sensors were additionally improved by insertion of
different fluorophores: mTurquoise, a cyan fluorescent pro-
tein with more than doubled quantum efficiency, single-
exponential fluorescence decay, and exceptional photo sta-
bility, was N-terminally fused to Epac [11], and an improved
yellow fluorophore cp173Venus-Venus was inserted at the C-
terminus. The latter double acceptor consists of mVenus, a
stable yellow fluorescent protein, and a circular permutation
of Venus (cp173Venus) [16] resulting in enhanced brightness,
acid stability, and stability to chloride changes. The combi-
nation of mTurquoise as a FRET donor and of cp173mVenus-
mVenus as a FRET acceptor resulted in higher FRET effi-
ciencies, enhanced photo stability, and an increased dynamic
range [11] and is referred to as the H74 construct [11].
Recently, additionally optimized Epac constructs were gen-
erated. The so-called H187 construct exhibits a 2.5-fold in-
creased affinity to cAMP due to an additional amino acid
exchange (Q270E) and displays higher photo stability and
higher FRET efficiencies by means of combining the
fluorophores mTurquoise2, the most photostable cyan
fluorophore at present, and a tandem of cp173Venus [10].
Although Epac-based cAMP sensors have constantly
been improved over the last few years, the use of these
sensors is largely restricted to the detection of cAMP in-
creases mediated by Gs-coupled receptors. Until now, Epac
sensors have not been employed to monitor Gi/o-mediated
cAMP decreases without pre-stimulation with forskolin or
IBMX to increase endogenous cAMP levels. To investigate
whether FRET-based sensors can principally be exploited
to reliably monitor cAMP level decreases following Gi/o-
activation and to systematically compare different Epac
cAMP sensors, two novel Epac constructs with higher pho-
to and acid stability based on the original Epac constructs
Epac1 and Epac2 were generated by us. In addition, the
original non-optimized [17] and the two abovementioned
optimized FRET-based Epac sensors [10, 11] were tested
as potential sensors of Gi/o-coupled receptor activation.
The systematic comparison of different Epac sensors
allowed defining essential parameters governing the detec-
tion of cAMP level decreases in single cells.
Results
Optimized FRET-based cAMP sensors are effective in
monitoring Gs-mediated cAMP level increases To investi-
gate whether Epac-based cAMP sensors can be employed to
detect cAMP decreases, we used a set of different Epac sen-
sors: four sensors which are well-established to monitor Gs-
protein-mediated cAMP increases (YFP-Epac1-CFP, YFP-
Epac2-CFP, H74, and H187) and two constructs with modi-
fied fluorochromes generated by us (mV-Epac1-mTq2, mV-
Epac2-mTq2) which are based on the original Epac1 and
Epac2 constructs. To test if all Epac-based cAMP constructs
were functional, we performed FRET measurements with
HEK293 cells endogenously expressing Gs-coupled adrener-
gic β2-adrenergic receptors (β2Rs) that were transfected with
one of the Epac constructs. Schematic structures of the five
Epac sensors are displayed in Fig. 1a–f (left panels). Agonist
stimulations with the β receptor agonist isoprenaline
(200 μM) increased cyan and simultaneously decreased yel-
low fluorescence resulting in FRETsignal decreases (Fig. 1a–
f) that reflect elevations of cAMP concentrations. Our results
show that all constructs were functional and suitable to detect
cAMP increases. However, the amplitudes of FRET signals
varied between −5.7 ± 0.7% in the case of mV-Epac1-mTq2
and −97.2 ± 12.9% in the case of the optimized Epac construct
H187. The summary of FRET signal amplitudes shows that
the FRET pair YFP/CFP was more efficacious than the FRET
pair mVenus/mTurquoise2 (Fig. 1g). Interestingly, there were







Fig. 1 Optimized FRET-based cAMP sensors are effective in monitoring
Gs-mediated cAMP level increases. FRET measurements with HEK293
cells endogenously expressing Gs-protein-coupled β2 receptors together
with one of the indicated FRET-based cAMP sensors: YFP-Epac1-CFP
(a), YFP-Epac2-CFP (b), mV-Epac1-mTq2 (c), mV-Epac2-mTq2 (d),
mTq-Epac-cpmVmV (H74) (e), and mTq2-Epac-cpmVcpmV (f). a–f
Representative FRET measurements are displayed showing time
courses of the normalized yellow and cyan fluorescence signals (left)
and of the normalized FRET signals (right). Black bars indicate
application of the β receptor agonist isoprenaline (200 μM). Left insets,
schematic illustration of the different FRET-based cAMP sensors Epac.
The Epac protein is N- and C-terminally fused to two fluorophores. If
cAMP is not bound to Epac, both fluorophores are in close proximity of
less than 10 nm to each other resulting in a FRET signal. Binding of
cAMP to Epac due to Gs-coupled receptor activation causes conforma-
tional change of the protein which results in greater distance of both
fluorophores which leads to FRET signal decreases. The white circle
displays the cAMP binding site in the Epac protein; cAMP is displayed
as red dot. g summary of FRET signal decreases induced by isoprenaline
in the presence (hatched bars) or absence (solid bars) of the selective β2
receptor antagonist propranolol (1.5 mM). Numbers over bars indicate
the numbers of measured cells and the number of individual coverslips
from at least 3 experimental days. Significances tested between
propranolol-treated and untreated cells. **P < 0.01, ***P < 0.001
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no significant differences in the detection of maximal cAMP
increases between Epac1 and Epac2 constructs. The smallest
FRET changes were obtained by the Epac1 and Epac2 con-
structs with the fluorophores mVenus and mTurqouise2 indi-
cating that enhanced stability of fluorochromes does not nec-
essarily result in higher FRET efficiency. Notably, highest
FRET amplitudes were monitored using the cytosolic FRET
constructs H74 (−43.8 ± 5.4%) and H187 that exhibited even
2.2-fold higher FRET amplitudes. These findings suggest that
H74 and H187 constructs are most suitable to detect increases
in cAMP concentrations concordant with observations by
Klarenbeek et al. [10, 11].
FRET-based cAMP sensors are suitable to monitor cAMP
decreases in living cells induced by activation of Gi/o-
coupled α2A receptors To elucidate, whether Epac sensors
are principally suitable to detect intracellular cAMP level de-
creases, we co-expressed Gi/o-coupled α2A receptors (α2AR)
with the Epac constructs YFP-Epac1-CFP, YFP-Epac2-CFP,
mV-Epac1-mTq2, and mV-Epac1-mTq2 and with the opti-
mized sensor H74. Agonist stimulations with the selective
α2AR agonist guanfacine (250 μM) were not sufficient to reli-
ably increase FRET signals. Thus, we pre-treated cells with
forskolin, an activator of AC, at a submaximal concentration
(1 μM) to slightly increase basal cAMP levels. Higher concen-
trations of forskolin up to 10 μM caused maximal cAMP ac-
cumulation that exceeded the dynamic range and could there-
fore not be reversed by application of agonists. Pre-incubation
with 1 μM forskolin plus 10μM IBMXwas not more effective
than forskolin alone (data not shown) and pre-incubation of
100 μM 8-Bromo-cAMP did not result in any reliable mea-
surements (data not shown). Thus, employing these Epac con-
structs without forskolin application, a reduction of intracellu-
lar cAMP concentrations could not be reliably determined,
similar to the situation with radioactive cAMP accumulation
assays. However, as soon as stable fluorescence baselines were
reached, application of 1 μM forskolin entailed increases of
cyan and decreases of yellow fluorescence resulting in de-
creased FRET signals (Fig. 2a–e). When stable fluorescence
baselines were established again, the selective agonist
guanfacine was applied resulting in FRET signal increases
(Fig. 2a–e) reflecting decreases of intracellular cAMP concen-
trations. The summary of FRET signal amplitudes illustrates
that the H74 construct was most efficient to detect cAMP de-
creases with FRET signal amplitudes of 17.4 ± 2.2% (Fig. 2f).
Just as in the case of Gs-dependent cAMP accumulation, the
FRET pair YFP/CFP resulted in FRET signals higher than the
mVenus/mTurquoise2 FRET pair, and there were no signifi-
cant differences in the maximal cAMP decreases between
Epac1 and Epac2 constructs. The smallest changes of FRET
signals of 3.7 ± 0.8% were monitored when using
mVenus-Epac2-mTurquoise2. Altogether, these findings sug-
gest that Epac-based cAMP sensors are suitable tools to
monitor Gi/o-protein-mediated decreases of intracellular
cAMP concentrations in single living cells if cells are pre-
treated with forskolin to elevate basal cAMP levels. In addi-
tion, these findings confirm that the FRETsensor H74 is highly
effective in detecting cAMP level fluctuations.
FRET-based cAMP sensors reliably detect cAMP level de-
creases induced by activation of Gi/o-protein-coupled μ
opioid receptors Next, we tested μ opioid receptors (μRs)
as another example of Gi/o-coupled receptors. First, HEK293
cells co-expressing μRs together with one of the Epac sensors
YFP-Epac1-CFP, YFP-Epac2-CFP, mV-Epac1-mTq, mV-
Epac1-mTq, or H74 were investigated. One micromolar of
forskolin had to be applied to slightly enhance basal cAMP
concentrations similar toα2AR-expressing cells, since without
this measure no significant FRETsignal changes upon agonist
application could be detected. Forskolin decreased FRET sig-
nals and subsequent application of the selective μR agonist
DAMGO (100 nM), a synthetic opioid peptide, lead to an
increase in FRET signals (Fig. 3a–e). The summary of differ-
ential FRET amplitudes shows that the H74 construct was
most efficient in detecting cAMP decreases with FRET am-
plitudes of 22.5 ± 2.1% (Fig. 3f). Moreover, the FRET pair
YFP/CFP was more effective than the FRET pair mVenus/
mTurquoise2 and there were no significant differences in the
maximal cAMP decreases between Epac1 and Epac2 con-
structs similar to the findings observed with α2A and β2 re-
ceptors. These findings confirm that after pre-incubation with
forskolin, Gi/o-induced cAMP decreases can be effectively
monitored by using the FRET technique.
Next, we asked whether the FRET sensor H187 character-
ized by a higher affinity to cAMP and a considerably in-
creased dynamic range might be sensitive enough to detect a
decline of cAMP levels without pre-treatment with forskolin.
Indeed, analyzing HEK293 cells co-expressing μR and the
H187 sensor, we found that agonist stimulation with
DAMGO resulted in FRET signal increases (Fig. 3f) indicat-
ing that this sensor is suitable to monitor cAMP decreases
without pre-incubation with forskolin. Maximal FRET signal
increases were already detectable following application of
100 nMDAMGO. Higher concentrations did not cause higher
FRET signal changes. The summary of FRET amplitudes
shows that agonist stimulation with DAMGO evokes en-
hanced FRET signals of 20.7 ± 1.6% (Fig. 3h) similar to the
FRET signals determined by analyzing the H74 construct in
the presence of forskolin. The EC50 value for DAMGO deter-
mined by analyzing H187 and μRs co-expressing HEK293
cells was 91 ± 53 pM (n = 3) (Fig. 3h, inset) demonstrating
a high potency of DAMGO. Altogether, these findings sug-
gest that the H187 construct is a preferable molecular tool to
monitor Gi/o-protein-mediated decreases of cAMP levels in a
concentration-dependent, time-resolved manner in single liv-
ing cells without the need of forskolin pre-treatment.
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Agonist-induced FRET signal changes can be suppressed
by selective receptor antagonists To investigate whether
agonist-induced FRET signals corresponding to increases or
decreases of cAMP levels are specific, selective receptor an-
tagonists were applied. We used propranolol (1.5 mM) to
block endogenously expressed β2Rs (Fig. 4a, d), yohimbine
(1 mM) to block α2ARs (Fig. 4b), and the synthetic cyclic
penicillamine-containing octapeptide (CTAP) (500 nM) to
block μRs (Fig. 4c, e). Antagonists were applied at concen-
trations that precluded receptor activation in the presence of
maximal agonist concentrations. Applying the β2R antagonist
propranolol, FRETsignals were remarkably smaller compared
to untreated cells (Figs. 1g and 4a, d). Similar results were
observed analyzing α2AR or μR and H74 or H187 sensor
co-expressing cells with or without pre-stimulation with
forskolin in the presence of yohimbine or CTAP (Figs. 2f,
3g, h, and 4b, c, e). Summarized FRET signal changes upon
application of selective antagonists show that antagonists sig-
nificantly reduce agonist-induced FRET signals elicited by









































































































































































Fig. 2 FRET-based cAMP
sensors are suitable to monitor
cAMP decreases in living cells
induced by activation of Gi/o-
coupled α2A receptors. FRET
measurements with HEK293 cells
expressing Gi/o-protein-coupled
α2A receptors together with one




showing time courses of the
normalized yellow and cyan
fluorescence signals (left) and of
the normalized FRET signal
(right). Black bars indicate
application of the adenylyl
cyclase activator forskolin (FSK)
in submaximal concentration
(1 μM) to increase basal cAMP
levels. Gray bars show
application of the selective α2A
receptor agonist guanfacine
(250 μM). f Summary of FRET
signal increases induced by
guanfacine in the presence
(hatched bars) or absence (solid
bars) of the selectiveα2A receptor
antagonist yohimbine (1 mM).
Numbers over bars indicate the
numbers of measured cells and
the number of individual
coverslips from at least 3
experimental days. Significances
tested between cells treated and
not treated with yohimbine.
*P < 0.05, **P < 0.01
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indicating that the observed FRET responses are specific.
However, FRET signals were not completely abrogated by
receptor antagonists.
Prerequisites for reliable and reproducible measurements
with FRET-based Epac sensors to detect Gi/o-protein-me-

































































































































































































































































Fig. 3 FRET-based cAMP sensors reliably detect cAMP level decreases
induced by activation of Gi/o-protein-coupled μ opioid receptors. FRET
measurements with HEK293 cells expressing Gi/o-protein-coupled μ
opioid receptors together with one of the indicated FRET-based Epac
constructs. a–f Representative FRET measurements are displayed
showing time courses of the normalized yellow and cyan fluorescence
signals (left) and of the normalized FRET signal (right). Black bars
indicate application of the adenylyl cyclase activator forskolin (1 μM,
FSK) in submaximal concentration to increase basal cAMP levels (a–
e). Gray bars show application of the selective μ receptor agonist
DAMGO (100 nM). g Summary of FRET signal increases induced by
DAMGO after forskolin pre-stimulation in the presence (hatched bars) or
absence (solid bars) of the selective μ receptor antagonist CTAP
(500 nM). Numbers over bars indicate the numbers of measured cells
and the number of individual coverslips from at least 3 experimental days.
h Summary of FRETsignal increases induced by 100 nMDAMGO in the
presence (hatched bars) or absence (solid bars) of CTAP (500 nM). Right
insets show representative FRET signal trace with application of
increasing concentrations of DAMGO (top) and the concentration
response curve displayed as mean ± s.e.m. of three independent
measurements (bottom). The curve was fitted using the Hill equation.
Numbers over bars indicate the numbers of measured cells and the
number of individual cover slips from at least 3 experimental days.
Significances tested between cells treated and not treated with CTAP.
*P < 0.05, **P < 0.01, ***P < 0.001
Pflugers Arch - Eur J Physiol
results using FRET-based Epac sensors to detect Gi/o-pro-
tein-mediated cAMP decreases with or without pre-
treatment with forskolin, it is of paramount importance to
equilibrate the system and reach steady-state conditions be-
fore applying any stimuli. Representative FRET measure-
ments of HEK293 cells endogenously expressing β2Rs or
transiently over-expressing μRs which were additionally
transfected with H74 are displayed in Fig. 5a, b to illustrate
the time period to steady-state conditions and the measuring
range of the fluorescence decay at steady-state conditions
that must be established before application of the first stim-
ulus. Steady-state conditions are characterized by constant
fluorescence traces without apparent fluorescence decay of
both fluorescence traces. In some experiments, after applica-
tion of forskolin (Fig. 5b), we had to wait for steady-state equil-
ibration a second time before applyingDAMGOentailing FRET
signal increases. The times to steady state before applying the
first stimulus varied between Epac constructs and the analyzed
receptors from 100 to 926 s with a mean time of 345 ± 13 s
(Fig. 5c–e). The second stimulus could be applied after a lag
period of 390 ± 17 s on average. Summarized fluorescence
changes of cyan and yellow fluorescence signals determined
as millivolts per second before application of the first stimulus
are displayed in Fig. 5f–h. Highest variations of fluorescence
changeswere foundwhen analyzingHEK293 cells endogenous-
ly expressing β2Rs (Fig. 5f). Under these conditions,
success rates of FRET measurements with different receptors
using the indicated cAMP sensors were as follows (Fig. 5i):
Analyzing HEK293 cells endogenously expressing β2Rs or
over-expressing α2ARs, we observed that 27 to 56% of all
measurements were successful employing the non-optimized
Epac1- and Epac2-based FRET sensors. The optimized H74
construct yielded success rates ranging between 61 and 70%.









































































































































Fig. 4 Agonist-induced FRET
signal changes can be suppressed




β2Rs or over-expressing Gi/o-
protein-coupled α2A or μ
receptors together with the FRET-
based Epac sensor H74 (a–c) or
H187 (d, e). a–e Representative
FRET measurements are
displayed with time courses of the
normalized yellow and cyan
fluorescence signals (left) and of
the normalized FRET signals
(right). Hatched bars indicate
application of the selective
antagonists propranolol (1.5 mM,
a, d), yohimbine (1.0 mM, b), and
CTAP (500 nM, c, e). Gray bars
show application of the agonists
isoprenaline (200 μM),
guanfacine (200 μM), and
DAMGO (100 nM). b, c
Application of the adenylyl
cyclase activator forskolin (1 μM,
FSK) in submaximal
concentration to increase basal
cAMP levels is displayed
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endogenously expressed β2Rs. Moreover, 53% of measure-
ments showed FRET signal increases induced by agonist stim-
ulation in the case of μRs co-expressing cells without
forskolin pre-treatment. Interestingly, the success rates not on-
ly depended on the Epac construct but also on the type of
receptor. Measurements with the μR after forskolin
pre-treatment were most successful with success rates up to
100%. There were no differences between success rates using
the optimized H74 construct or YFP-Epac2-CFP or
mV-Epac2-mTq2. In these experiments, the Epac2 sensors
and H74 performed equally well. However, the H74 sensor
is characterized by a wider dynamic range with higher FRET
amplitudes rendering H74 the most preferable cAMP sensor.
Although the success rate using the H187 construct with μRs
co-expressing cells was lower, this construct showed an ade-
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had an increased affinity to cAMP. Thus, this construct is well
suitable to monitor small changes of intracellular cAMP concen-
trations without artificially increasing basal cAMP levels.
To analyze the kinetics of FRETsignal changes after recep-
tor stimulation, we fitted the FRET signal curves of H74 and
H187 sensor-expressing cells during agonist stimulation by a
monoexponential function. The kinetics of α2AR- and μR-
induced FRET signal changes were not significantly different
(Fig. 5j, k) independent of the FRET sensor employed.
Notably, the kinetics of cAMP increases by stimulation of
endogenous β2Rs using H74 and H187 constructs was not
significantly different and showed absolute values of time
constants (half-time, τ1/2) similar to those observed with
Gi/o-coupled receptors (Fig. 5j, k). These findings support
the conclusion that the cAMP sensors H74 and H187 are
suitable to determine the kinetics not only of cAMP level
increases by Gs-activation but also of cAMP decreases subse-
quent to Gi/o-stimulation.
Discussion
Dynamic intramolecular FRET using Epac-based cAMP sen-
sors to determine intracellular cAMP concentration variations
resulting from activation of Gs-coupled receptors in living
cells is a well-established method. Until now, this technique
was applied to monitor Gs-induced cAMP level increases. In
this study, we optimize the methodology and show for the first
time that Epac-based cAMP sensors are sufficiently dynamic
to allow for the detection of Gi/o-dependent cAMP decreases
as well. Interestingly, employing the most sensitive Epac sen-
sor H187, we found that artificially increasing endogenous
basal cAMP levels with forskolin or IBMXwas not necessary
to monitor Gi/o effects. Forskolin and IBMX are widely used
to increase basal cAMP levels in order to monitor cAMP level
decreases mediated by Gi/o-protein activation. The adenylyl
cyclase activator forskolin leads to cAMP increases resulting
in protein kinase A (PKA) activation thereby changing the
overall phosphorylation status, which might cause sensitiza-
tion or desensitization of GPCRs and other signaling proteins.
IBMX is a non-selective phosphodiesterase inhibitor which
additionally increases cyclic guanosine monophosphate
(cGMP) levels. Moreover, IBMX inhibits tumor necrosis fac-
tor TNFα [5, 14] and is a non-selective adenosine receptor
antagonist [26]. Altogether, IBMX and forskolin engage sev-
eral signaling pathways thereby evoking adverse effects,
which might influence the receptor status. Thus, avoiding
the use of these substances is a major advantage.
In our study, Gi/o-protein-mediated FRET signal increases
were receptor-specific and could be significantly suppressed
by selective antagonists similar to Gs-protein-mediated FRET
signals. Using FRET sensors based on Epac1 and Epac2 and
the optimized H74 construct, we found that a prerequisite for
reliable FRET measurements of Gi/o-mediated cAMP de-
creases was pre-treatment of the cells with the adenylyl cy-
clase activator forskolin at submaximal concentrations similar
to biochemical multi-cell radioactive labeling assays. Since
these sensors were well suitable for the detection of FRET
increases corresponding to cAMP decreases induced by α2A
and μ receptors, these findings show that Epac sensors can be
employed to analyze Gi/o-activation. However, quality and
reproducibility of measurements strongly depended on the
establishment of steady-state conditions of the fluorescence
signal prior to application of forskolin and/or agonists. There
were differences between the different FRET constructs re-
garding the success rates and the dynamic range of the ob-
served FRET signals. The H74 construct was found to be
preferable when monitoring FRET signals induced by Gi/o-
proteins subsequent to forskolin pre-treatment. However,
forskolin administration was no longer required when using
the latest FRET construct H187 which exhibits a higher affin-
ity to cAMP. This sensor showed a higher dynamic range than
the H74 sensor analyzing Gs-coupled receptor activation.
Moreover, due to enhanced cAMP affinity, the H187 sensor
already responds to small cAMP alterations. Therefore, the
latter sensor allowed for the detection of decreased basal
cAMP levels in HEK293 cells obviating the need for pre-
stimulation with forskolin. Interestingly, using the H187
Fig. 5 Prerequisites for reliable and reproduciblemeasurements with FRET-
based Epac sensors to detect Gi/o-protein-mediated cAMP decreases. For
reliable and reproducible FRET measurements with FRET-based Epac
sensors, achievement of steady-state conditions prior to application of
different stimuli was of utmost importance. a, b Representative FRET
measurement of HEK293 cells endogenously expressing β2Rs (a) or
over-expressing μRs (b) and the H74 construct. The time courses of the
normalized yellow and cyan fluorescence signals (left) and of the
normalized FRET signal (right) are displayed. Isoprenaline (200 μM,
black bar, a) or forskolin (1 μM, FSK, black bar, b) are applied at
steady-state conditions (time to steady state is indicated as white bar).
The second stimulus DAMGO (100 nM, gray bar) is applied when
steady-state conditions are achieved (time to steady state of FSK is
indicated as a white bar, b). a, b Light gray bars indicate steady-state
conditions used to determine the range of fluorescence changes as
millivolts per second (left). c–e Summaries of the times to steady state
of β2R (c), α2AR (d), or μR (e) and different indicated Epac sensor-
expressing HEK293 cells. Results are displayed as boxplot analysis
plus single values. Squares indicate mean values. Numbers over bars
indicate the numbers of measured cells from at least 3 experimental
days. f–h Slopes of the yellow and cyan florescence traces of β2R (f),
α2AR (g), or μR (h) and different Epac sensor-expressing HEK293 cells
determined before application of the first stimulus. *Fluorescence was
detected as voltage of the transimpedance amplifier from the
photodiode. i Summary of success rates of FRET measurements with
HEK293 cells co-expressing different receptors and indicated FRET-
based Epac sensors. Numbers over bars indicate the numbers of
measured cells from at least 3 experimental days. j, k Analysis of the
kinetics of FRET signal changes using the H74 (j) or the H187 sensor (k)
after Gs- or Gi/o-coupled receptor activation calculated as exponential
time constant as τ1/2 displayed as boxplot analysis plus single values.
Squares indicate mean values. Numbers indicate the numbers of
measured cells from at least 3 experimental days
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construct, the EC50 value for DAMGO was decreased to
91 pM indicating a superior sensitivity. Employing the classi-
cal radioactive assay based on the conversion to 3H-cAMP, a
nearly 100-fold higher EC50 value of 8.4 nM was determined
for DAMGO [4]. Notably, a comparable EC50 value of
320 pM was calculated when monitoring DAMGO-induced
calcium transients in CHO-K1 cells stably expressingμRs and
Gα15 proteins [8] without forskolin pre-incubation. Thus,
circumventing pre-stimulation with forskolin appears to in-
crease the potency of agonists and the overall sensitivity of
the assay. Moreover, wemonitored FRETsignals on the single
cell level instead of performing multicellular assays in which
the signal represents an average of all cells including non-
responding and damaged cells that may affect sensitivity.
Thus, taking advantage of the H187 sensor represents a con-
siderable improvement compared to multicellular radioactive
assays.
Another prerequisite for reliable measurements of Gi/o-me-
diated cAMP level decreases consists of equilibration of the
system to achieve steady-state conditions of fluorescence sig-
nals prior to stimulation. Under these conditions, FRET mea-
surements were characterized by success rates of 27 to 100%
depending on the FRET construct and the receptor analyzed.
Although all Epac sensors can principally be applied to dynam-
ically monitor intracellular cAMP concentrations, the dynamic
ranges of FRET signals varied considerably. Constructs mV-
Epac1-mTq2 and mV-Epac2-mTq2 engineered by us showed
the smallest FRET signal amplitudes, while H74 and H187
constructs had the highest dynamic range.
Apart from Epac sensors, there are several other methods,
which are suitable to measure Gi/o-protein-mediated signaling.
Generally, they can be classified as multi-cell and single-cell
assays. Multi-cell assays comprise radioactive and
non-radioactive methods and can either be based on the anal-
ysis of cell membrane fractions or of intact living cells.
Notably, analysis of membrane preparations can only give
information at one time point and is not suitable to detect
dynamic changes of cellular signals. A common approach to
monitor G-protein activation using cell membrane prepara-
tions is the radioactive [35S]GTPγS binding assay which is
highly sensitive [15] and does not require pre-stimulation with
forskolin. However, [35S]GTPγS binding studies are not selec-
tive for Gi/o-protein activation. Other multi-cell assays moni-
tor cAMP accumulation as an end point measurement without
time-resolved monitoring of cAMP changes. In addition to the
classical 3H-adenine pre-labeling approach, competition as-
says based on radiometric or immunoassay techniques are
widely used. Several radiometric cAMP accumulation assays
such as RIA, ELISA, scintillation, and chemiluminescence
proximity assays are commercially available and are even
suitable for high-throughput screening (summarized in [9]).
Other multi-cell approaches use label-free technologies with
electrical or optical measurement systems (summarized in [7,
32]) and can monitor GPCR activation in intact living cells.
Interestingly, these approaches allow for real-time detection of
signal changes. However, the signal is only a summation of all
biochemical, physiological, and morphological responses of
cells and neither provides detailed information about the sig-
naling cascade nor does it allow to draw conclusions about
cAMP levels. Altogether, multi-cell assays are not suitable to
detect cAMP changes with spacial and temporal resolution.
On the single cell level, Gi/o-protein activation can be moni-
tored with various biosensors. One possibility is the determina-
tion of G-protein activation in single living cells using biosen-
sors based on the dissociation of the heterotrimer after G-protein
activation. An example is the detection of Gi/o-activation
employing the FRET technique which comprises the use of
Gαi FRETsensors [30]. This method is based on intermolecular
FRET between cp173mVenus-Gγ as a FRET acceptor and Gαi-
mTurquoise2 as a FRET donor. These sensors allow the record-
ing of the fast kinetics of Gi-activation. However, the method
relies on the over-expression of G-protein subunits which may
strongly influence the stoichiometry of receptors and G-proteins
thereby impacting activation kinetics and potentially obfuscating
the physiological preference of a given receptor for a defined
composition of heterotrimeric G-proteins. FRET measurements
with the Epac sensors benefit from the fixed 1:1 or 1:2 donor/
acceptor stoichiometry which cannot be provided by using a
multicistronic expression vector for three G-protein subunits.
In the case of using the Epac sensors, endogenous G-proteins
are not influenced. Thus, Epac sensors may be molecular tools
of choice if intracellular cAMP concentrations are to be moni-
tored as a readout for Gi/o-activation. Conversely, Gαi FRET
sensors may be advantageous when intending to characterize
the kinetics of Gi-activation.
Apart from Epac sensors, cAMP-binding biosensors are
available which are based on protein kinase A (PKA) or on
cyclic nucleotide-gated (CNG) channels. PKA-based sensors
consist of catalytic and regulatory subunits of PKA, which are
labeled with fluorophores. In the absence of cAMP, the sub-
units form a tetrameric holoenzyme complex. Binding of four
cAMP molecules to the regulatory subunits causes dissocia-
tion of the catalytic subunits resulting in FRET signal de-
creases (summarized in [9]). Interestingly, PKA- and Epac-
based biosensors can be targeted to the plasma membrane
resulting in more rapid signals with greater amplitudes. In
addition, mitochondria- and nuclear-targeted cAMP FRET
sensors have been developed [6] which allow for subcellular
analysis of cAMP signals. However, a disadvantage of PKA
biosensors is their slower kinetics compared to Epac sensors.
CNG and related hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels can also be used as cAMP
biosensors. These biosensors were optimized to obtain a se-
lectivity for cAMP over cGMP. cAMP signal increases cause
channel activation which can be measured by performing
patch-clamp measurements or calcium imaging (summarized
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in [19, 27, 31]). The major advantage of this biosensor is the
temporal resolution of the cAMP signal rendering this sensor
well suitable for kinetic analysis. In addition, a cytosolic HCN
channel-based FRET biosensor (HCN2-camps) was generated
which even allows for analysis of cAMP changes in subcellu-
lar compartments [18]. All CNG channel-based biosensors are
well suitable to monitor cAMP level increases. However,
these biosensors require high basal cAMP levels to detect
Gi/o-mediated cAMP level decreases and are therefore not
optimal for the analysis of Gi/o-mediated signaling. An alter-
native approach to measure Gi/o-mediated signaling is the
analysis of G-protein-gated inwardly rectifying potassium
channels Kir 3.1–3.4 [1] which are directly activated by βγ
subunits of Gi/o-proteins [13]. However, direct monitoring of
cAMP levels is not possible. Furthermore, the use of the
patch-clamp technique as a readout is time-consuming and
technically demanding.
Altogether, our findings provide a robust experimental
framework allowing to utilize Epac-based cAMP sensors to
functionally characterize Gi/o-coupled receptors and to moni-
tor cAMP decreases upon Gi/o-activation in single living cells
under physiological conditions.
Methods
FRET-based cAMP sensors used in the study
The FRET-based cAMP sensors eYFP-hEpac1-eCFP (YFP-
Epac1-CFP) and eYFP-mEpac2B-eCFP (YFP-Epac2-CFP) in
pcDNA3.1 vector were used [17]. To obtain more stable fluo-
rochromes with higher quantum efficiency, photo stability,
and strictly single-exponential fluorescence decay, we ex-
changed enhanced cyan fluorescent protein (eCFP) with
mTurquoise2 and enhanced yellow fluorescent protein
(eYFP) with the less pH- and Cl−-sensitive yellow fluorescent
protein mVenus. For this, the inserts mVenus and mTurqoise2
additionally containing restriction sites for HindIII and EcoRI
and for Xbal and NotI were amplified with by PCR using the
following primer pairs: for mVenus 5′-AAATTA AGC TTA
TGG TGA GCA AGG GCG AGG A-3′ (sense) and 5′-AAA
TTG AAT TCC TTG TAC AGC TCG TCC ATG C-3′ (anti
sense) and for mTurquoise2 5′-AAA TTT CTA GAG TGA
GCA AGG GCG AGG AGC T-3′ (sense) and 5′-AAA TTG
CGG CCG CTT ACT TGT ACA GCT CGT CCAT-3′ (anti
sense). The complementary DNA (cDNA) templates YFP-
Epac1-CFP and YFP-Epac2-CFP in pcDNA3.1 vector were
digested with XbaI und NotI to cut out eCFP. Next, eCFP was
replaced by ligation with mTurquoise2. The mTurqoiuse2-
containing cDNA templates were digested with HindIII und
EcoRI to remove eYFP that was subsequently replaced by
mVenus. Thus, we obtained two new FRET sensors:
mVenus-hEpac1-mTurqouise2 (mV-Epac1-mTq2) and
mVenus-mEpac2B-mTurquoise2 (mV-Epac2-mTq2).
Moreover, the following optimized Epac-based constructs
were used: mTurquoise-Epac-cp173mVenus-mVenus (mTq-
Epac-cpmVmV or H74 [11]) which lacks the membrane-
targeting DEP sequence (ΔDEP) and catalytic activity due
to an amino acid exchange in the guanine nucleotide exchange
factor (GEF) domain [21] and the construct mTurquoise2-
Epac(Q270E)-cp173mVenus- cp173mVenus (mTq2-
Epac-cpmVcpmVor H187 [10]) with an additional point mu-
tation resulting in higher cAMP affinity.
Cell culture and transfections
Human embryonic kidney (HEK293) cells were maintained in
Earl’s minimal essential medium (Sigma-Aldrich, Taufkirchen,
Germany) supplemented with 100 U ml−1 penicillin,
100 μg ml−1 streptomycin, 10% fetal calf serum (FCS,
Gibco, USA), and 2 mM glutamine and held at 37 °C in a
humidified atmosphere with 5% CO2. For FRET measure-
ments, HEK293 cells were seeded into six-well plates and
transfected with one of the following FRET-based cAMP sen-
sors, 0.4 μg eYFP-Epac1-eCFP, 0.4 μg eYFP-Epac2-eCFP,
0.3 μg mVenus-Epac1-mTurquoise2, 0.3 μg mVenus-Epac2-
mTurquoise2 or 0.3 μg mTurquoise-Epac-cp173mVenus-
mVenus (H74 construct), and 0.3 μg mTurquoise2-
Epac(Q270E)-cp173mVenus-cp173mVenus (H187 construct),
and with one of the following GPCRs, 1 μg human α2A
adrenoceptor (NM_000681) or 1 μg human μ receptor
(AY521028). For analysis of Gs-activation, endogenously
expressed β2 receptors were used. HEK293 cells were
transfected at a cell confluency of about 90% by lipofection
with GeneJuice® (Merck Millipore, Schwalbach, Germany)
according to the manufacturer’s instructions. Cells were mea-
sured 24 h after transfection. Prior to FRET experiments,
transfected HEK293 cells were seeded onto glass bottom
dishes (FluoroDish Cell Culture Dish, 35 mm with glass bot-
tom 23 mm, WPI, Berlin, Germany) coated with poly-L-lysine
(Sigma-Aldrich). For coating, 1 ml poly-L-lysine solution
(0.1 mg ml−1) was applied and incubated at room temperature
for 60 min. After washing with 2 ml sterile Dulbecco’s
phosphate-buffered saline (DPBS, Sigma-Aldrich), cells were
seeded onto coated glass bottom dishes approximately 15 h
prior to experimentation.
FRET measurements
To measure changes of intracellular cAMP concentrations in
single living cells mediated by Gs- or Gi/o-coupled receptor
activation, FRET-based Epac sensors were used as described
previously [17]. In brief, FRET experiments were carried out
at room temperature and were conducted using a dual-
emission photometry system (TILL Photonics, Planegg,
Germany) on the stage of an Olympus IX70 inverted
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microscope equipped with an UPlanSAPO 100×/1.40 oil ob-
jective (Olympus, Hamburg, Germany). Upon excitation at
430 nm with Polychrome V (Till Photonics), fluorescence
intensities at 480 ± 20 and 535 ± 15 nm were measured with
the dual-emission photometry system using a beam splitter
DCLP 505 nm. Emission was measured as voltage of the
transimpedance amplifier of the photodiodes with a frequency
of 5 kHz and was collected by an EPC10 amplifier (HEKA,
Lambrecht, Germany) with the PATCHMASTER software
(HEKA). FRET ratios were determined as ratios of eYFP,
mVenus, cp173mVenus-mVenus, or cp173mVenus-cp173mVenus
and eCFP, mTurquoise, or mTurquoise2 emissions.
Normalized ratios were calculated from the corrected emis-
sion intensities. Fluorescence was corrected off-line for
bleed-through of CFP (48%) or mTurquoise and
mTurquoise2 (41.0%) into the 535 nm channel. Likewise,
bleed-through of eYFP (6.3%), mVenus, cp173mVenus-
mVenus, or cp173mVenus-cp173mVenus (6.3%) into the
480 nm channel was subtracted off-line. The corrected fluo-
rescence was used to calculate the corrected FRET ratio.
Fluorescence traces were not corrected for photo-bleaching
since stimuli were only applied when constant fluorescence
values and steady-state conditions were reached. During mea-
surements, cells were continuously superfused with HEPES-
buffered saline (HBS) solution containing 140 mM NaCl,
5.4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose,
and 10 mM HEPES (pH 7.4 with NaOH) resulting in an os-
molarity of 295–302 mOsm kg−1. In some experiments, bas-
al intracellular cAMP levels prior to Gi/o-protein activation
were increased by superfusion with HBS solution addition-
ally containing submaximal concentrations of forskolin
(1 μM, BIOZOL, Eching, Germany). Agonist stimulations
were performed by applying guanfacine (250 μM, Tocris,
Wiesbaden-Nordenstadt, Germany), isoprenaline (200 μM,
Sigma-Aldrich), and DAMGO (100 nM, Sigma-Aldrich) in
maximal effective concentrations. For some experiments,
the selective receptor antagonists yohimbine (1 mM,
Sigma-Aldrich), propranolol (1.5 mM, Sigma-Aldrich), or
CTAP (500 nM, Tocris) were added to the bath solutions in
concentrations that were effective to reverse agonist-
induced cAMP level alterations.
Statistical analysis
Data are presented as means ± standard error of the mean
(s.e.m.). Unless stated otherwise, data were compared by a
paired or unpaired Student’s t test, if a Gaussian distribution
was confirmed by applying a Shapiro-Wilk (normality) test,
and significance was accepted at P < 0.05 (*P < 0.05,
**P < 0.01, ***P < 0.001, n.s. P > 0.05). Some pieces of data
were displayed by boxplot analysis (percentiles 25 and 75%)
with additional mean values. The changes of FRET signals
during agonist stimulation were fitted with a mono-
exponential function applying simplex algorithms and
Levenberg-Marquardt iterations, until no reduction of chi-
square was notable. Bi-exponential functions did not provide
a better fit. Measurements were excluded if the fit did not
converge. For calculation of EC50 values, a concentration re-
sponse curve was fitted using the single Hill equation until no
reduction of chi-square was notable.
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